Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer

NCT01359397 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

OTHER

Sponsor class

Conditions

Metastatic Gastric Cancer
Adenocarcinoma of the Gastro-oesophageal Junction

Interventions

DRUG: Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab
DRUG: Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab

Sponsor

The Netherlands Cancer Institute